Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P82933

UPID:
RT09_HUMAN

ALTERNATIVE NAMES:
28S ribosomal protein S9, mitochondrial

ALTERNATIVE UPACC:
P82933; Q6PG40

BACKGROUND:
Small ribosomal subunit protein uS9m, alternatively known as 28S ribosomal protein S9, mitochondrial, is integral to mitochondrial ribosomes. This protein is vital for the synthesis of proteins within mitochondria, underscoring its significance in maintaining mitochondrial health and overall cellular energy homeostasis. The role of uS9m in the mitochondrial ribosome underscores its importance in the translation process of mitochondrially encoded proteins, crucial for proper mitochondrial operations.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Small ribosomal subunit protein uS9m holds promise for uncovering new therapeutic avenues. Given its central role in mitochondrial protein synthesis, targeting uS9m could offer novel strategies for treating mitochondrial disorders or enhancing mitochondrial function in disease states.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.